India has the highest number of tuberculosis (TB) patients in the world. Our country accounts for 23% of global TB cases and deaths. An estimated 2.2 million people suffer from TB in India with over 70,000 being multi-drug resistant (MDR) TB patients. In an effort to tackle the growing problem of resistant tuberculosis, recently the government of India approved a new drug called Bedaquiline to treat the extensively drug-resistant tuberculosis (MDR) which defies cure.
So, How Does The New Drug Work?
The drug has a novel mechanism of action by which it inhibits a critical enzyme – ATP synthase, required for protein synthesis of bacteria that cause TB. The drug also has the ability to rapidly kill TB bacteria, thereby eliminating them from the patient’s sputum to make him non-infectious. Therefore, this drug has a huge potential and can have a huge positive impact on controlling the spread of TB in…
View original post 143 more words